Latest News and Press Releases

心房細動の中国人の患者で抗凝固剤を処方されているのは26％未満であり、また、日本のがん患者の3分の1近くは、十分な治療を受けていない 中国のがん患者の約63％が最初に診断を受けてから6ヶ月以内に静脈血栓塞栓症を発症 アベラシマブはすでに北米、欧州、アジア太平洋地域のその他の諸国の、23ヶ国で試験中 マサチューセッツ州ケンブリッジ発, June 09, 2023 (GLOBE...

不足 26% 的中国房颤患者接受抗凝剂治疗，而在日本近三分之一的患者未得到充分治疗 在中国约 63% 的癌症患者在确诊后的前 6 个月内出现静脉血栓栓塞症 Abelacimab 已在 23 个国家/地区进行研究 包括北美、欧洲和亚太地区的其他地方 马萨诸塞州剑桥市, June 09, 2023 (GLOBE NEWSWIRE) -- Anthos Therapeutics...

Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China...

Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient...

Additional presentation spotlights GARDENIA registry design in patientswith atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer...

FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3...

This is the second Fast Track designation issued by the FDA for abelacimab Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and Factor XIa with high...

Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials The MAGNOLIA study will compare abelacimab against the current standard of care for VTE in cancer associated...